The total market size of DKD in the 7MM is approximately USD ~7,200 million in 2023 and is projected to increase during the forecast period (2024–2034).

Diabetic Kidney Disease Market Size, Treatment Market

Diabetic Kidney Disease Infographic

1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF DKD
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. DIABETIC KIDNEY DISEASE MARKET OVERVIEW AT A GLANCE
6.1. MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DKD IN 2020 IN THE 7MM
6.2. MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DKD IN 2034 IN THE 7MM
7. DISEASE BACKGROUND AND OVERVIEW
7.1. INTRODUCTION
7.2. CLASSIFICATION
7.3. PATHOPHYSIOLOGY
7.4. RISK FACTOR
7.5. DIAGNOSIS
8. TREATMENT
8.1. TREATMENT GUIDELINES
8.1.1. American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO): A Consensus Report
8.1.2. Japanese Clinical Practice Guideline for Diabetes 2020
8.1.3. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD: Key Takeaways
9. EPIDEMIOLOGY AND PATIENT POPULATION
9.1. KEY FINDINGS
9.2. ASSUMPTION AND RATIONALE
9.3. TOTAL PREVALENT CASES OF DIABETES IN THE 7MM
9.4. TOTAL PREVALENT CASES OF DKD IN THE 7MM
9.5. DIAGNOSED PREVALENT CASES OF DKD IN THE 7MM
9.6. THE UNITED STATES
9.6.1. Total Prevalent Cases of DKD in the United States
9.6.2. Diagnosed Prevalent Cases of DKD in the United States
9.6.3. Age-specific cases of DKD in the United States
9.6.4. Stage-specific cases of DKD in the United States
9.7. EU4 AND THE UK
9.7.1. Total Prevalent Cases of DKD in EU4 and the UK
9.7.2. Diagnosed Prevalent Cases of DKD in EU4 and the UK
9.7.3. Age-specific cases of DKD in EU4 and the UK
9.7.4. Stage-specific cases of DKD in EU4 and the UK
9.8. JAPAN
9.8.1. Total Prevalent Cases of DKD in Japan
9.8.2. Diagnosed Prevalent Cases of DKD in Japan
9.8.3. Age-specific cases of DKD in Japan
9.8.4. Stage-specific cases of DKD in Japan
10. PATIENT JOURNEY
11. MARKETED THERAPIES
11.1. KEY COMPETITORS
11.2. JARDIANCE (EMPAGLIFLOZIN): BOEHRINGER INGELHEIM/ELI LILLY
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Clinical Developmental Activities
11.2.4.1. Clinical Trial Information
11.2.5. Safety and Efficacy
11.3. KERENDIA (FINERENONE): BAYER
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Safety and Efficacy
11.4. INVOKANA/CANAGLU (CANAGLIFLOZIN): JOHNSON &amp; JOHNSON/ MITSUBISHI TANABE PHARMA
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Other Developmental Activities
11.4.4. Safety and Efficacy
11.5. FARXIGA/FORXIGA (DAPAGLIFLOZIN): ASTRAZENECA
11.5.1. Product Description
11.5.2. Regulatory Milestones
11.5.3. Other Developmental Activities
11.5.4. Safety and Efficacy
12. EMERGING THERAPIES
12.1. KEY COMPETITORS
12.2. MINNEBRO (ESAXERENONE/CS-3150): DAIICHI SANKYO
12.2.1. Product Description
12.2.2. Other Developmental Activity
12.2.3. Clinical Development
12.2.3.1. Clinical Trials Information
12.2.4. Safety and Efficacy
12.3. REACT (RENAL AUTOLOGOUS CELL THERAPY): PROKIDNEY
12.3.1. Product Description
12.3.2. Other Developmental Activity
12.3.3. Clinical Development
12.3.3.1. Clinical Trials Information
12.3.4. Safety and Efficacy
12.4. ZIBOTENTAN + DAPAGLIFLOZIN: ASTRAZENECA
12.4.1. Product Description
12.4.2. Other Developmental Activity
12.4.3. Clinical Development
12.4.3.1. Clinical Trials Information
12.4.4. Safety and Efficacy
12.5. VYLEESI (BREMELANOTIDE): PALATIN
12.5.1. Product Description
12.5.2. Other Developmental Activity
12.5.3. Clinical Development
12.5.3.1. Clinical Trials Information
12.6. TOZORAKIMAB (MEDI3506) + DAPAGLIFLOZIN: ASTRAZENECA
12.6.1. Product Description
12.6.2. Clinical Development
12.6.2.1. Clinical Trials Information
12.6.3. Safety and Efficacy
12.7. ATRASENTAN: CHINOOK THERAPEUTICS/NOVARTIS
12.7.1. Product Description
12.7.2. Other Developmental Activity
12.7.3. Clinical Development
12.7.3.1. Clinical Trials Information
12.7.4. Safety and Efficacy
12.8. LORUNDROSTAT: MINERALYS THERAPEUTICS
12.8.1. Product Description
12.8.2. Other Developmental Activity
12.8.3. Clinical Development
12.8.3.1. Clinical Trials Information
12.9. BI 690517 + EMPAGLIFLOZIN: BOEHRINGER INGELHEIM
12.9.1. Product Description
12.9.2. Other Developmental Activity
12.9.3. Clinical Development
12.9.3.1. Clinical Trials Information
12.9.4. Safety and Efficacy
12.1. INV-202: INVERSAGO PHARMA
12.10.1. Product Description
12.10.2. Other Developmental Activity
12.10.3. Clinical Development
12.10.3.1. Clinical Trials Information
13. DIABETIC KIDNEY DISEASE (DKD): SEVEN MAJOR MARKET ANALYSIS
13.1. KEY FINDINGS
13.2. TOTAL MARKET SIZE OF DKD IN THE 7MM
13.3. MARKET OUTLOOK
13.4. CONJOINT ANALYSIS
13.5. KEY MARKET FORECAST ASSUMPTIONS
13.6. UNITED STATES MARKET SIZE
13.6.1. Total Market Size of DKD in the United States
13.6.2. Market Size of DKD by Therapies in the United States
13.7. EU4 AND THE UK MARKET SIZE
13.7.1. Total Market Size of DKD in EU4 and the UK
13.7.2. Market Size of DKD by Therapies in EU4 and the UK
13.8. JAPAN MARKET SIZE
13.8.1. Total Market Size of DKD in Japan
13.8.2. Market Size of DKD by Therapies in Japan
14. UNMET NEEDS
15. SWOT ANALYSIS
16. KOL VIEWS
17. MARKET ACCESS AND REIMBURSEMENT
17.1. UNITED STATES
17.1.1. Centre for Medicare and Medicaid Services (CMS)
17.2. EU4 AND THE UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. United Kingdom
17.3. JAPAN
17.3.1. MHLW
17.4. DIABETIC KIDNEY DISEASE: MARKET ACCESS AND REIMBURSEMENT
17.4.1. United States Market Access and Reimbursement
17.4.2. Institute for Quality and Efficiency in Health Care (IQWiG): Germany
17.4.3. Haute Autorit&eacute; de Sant&eacute; (HAS): France
17.4.4. Italian Medicines Agency (AIFA): Italy
17.4.5. Spanish Agency of Medicines and Medical Products (AEMPS): Spain
17.4.6. The National Institute for Health and Care Excellence (NICE): UK
17.4.7. Japan Market Access and Reimbursement
18. APPENDIX
18.1. BIBLIOGRAPHY
18.2. REPORT METHODOLOGY
19. DELVEINSIGHT CAPABILITIES
20. DISCLAIMER
 
21. ABOUT DELVEINSIGHT

Diabetic Kidney Disease Market

Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology And Market Forecast - 2034

DelveInsight's Diabetic Kidney Disease (DKD) Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Diabetic Kidney Disease (DKD), historical and forecasted epidemiology as well as the Diabetic Kidney Disease (DKD) market trends in 7MM.